-+ 0.00%
-+ 0.00%
-+ 0.00%

Citizens Maintains Market Outperform on KalVista Pharmaceuticals, Lowers Price Target to $28

Benzinga·03/26/2026 13:04:05
Listen to the news
Citizens analyst Jonathan Wolleben maintains KalVista Pharmaceuticals (NASDAQ:KALV) with a Market Outperform and lowers the price target from $29 to $28.